Live Breaking News & Updates on Primary Immunodeficiencies|Page 2

Stay updated with breaking news from Primary immunodeficiencies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pharming To Develop Leniolisib For Additional PIDs Beyond APDS; Phase 2 Trial To Initiate In Q2

Dutch biopharmaceutical company Pharming Group N.V. (PHAR) announced Wednesday its plans to develop leniolisib for additional primary immunodeficiencies or PIDs beyond activated phosphoinositide 3-kinase delta syndrome or APDS. ....

Beth Israel Lahey Health , More Such Health News , Clinical Immunodeficiency Program , Pharming Group , Drug Administration , Phase 2 Trial , Primary Immunodeficiencies , Harming Leniolisib ,